Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic ...
The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback